| Bioactivity | Methimazole is an antithyroid compound widely used for the research of hyperthyroidism. Methimazole has potent hepatotoxicity[1][2]. | ||||||||||||
| Invitro | Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes[3]. | ||||||||||||
| Name | Methimazole | ||||||||||||
| CAS | 60-56-0 | ||||||||||||
| Formula | C4H6N2S | ||||||||||||
| Molar Mass | 114.17 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Tatara MR, et al. Effects of long-term oral administration of methimazole on femur and tibia properties in male Wistar rats. Biomed Pharmacother. 2017 Oct;94:124-128. [2]. Reza Heidari, et al. Mechanisms of methimazole cytotoxicity in isolated rat hepatocytes. Drug Chem Toxicol. 2013 Oct;36(4):403-11. [3]. Crescioli C, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol. 2007 Oct;195(1):145-55. [4]. Nakamura H, et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2007 Jun;92(6):2157-62. Epub 2007 Mar 27. |